PARP1 and small cell lung carcinoma: It is noteworthy that multiple clinical trials have been carried out since 2019, demonstrating the efficacy of PARP inhibitors not only limited to BRCA gene-mutated ovarian cancer and breast cancer but also in prostate cancer, pancreatic cancer, and small cell lung carcinoma (SCLC), irrespective of the BRCA gene status (110, 112–118).